Company Research Report: Digitalis Ventures
Company Overview
- Name: Digitalis Ventures
- Mission: Digitalis Ventures invests in solutions to unmet needs in health. The company leverages deep technical, financial, and domain expertise to creatively finance, build, and scale enduring enterprises.
- Founded: No specific founding date provided.
- Founders: Dr. Thomas W. Smith (The father of the founding partner began his career as a physician-scientist at Harvard and influenced the company's foundational inspiration).
- Key People:
- Geoffrey W. Smith – Founder/Managing Partner
- Misti Ushio – Managing Partner
- Samuel Bjork – Partner
- Amit Bansal – Partner
- Drew Taylor – Partner
- Ben Jacobs – Partner
- Dac Nguyen – Technical Partner
- Cindy Cole – Technical Partner
- Steve Allen – Venture Partner
- Headquarters: 11 Times Square, Suite 1500A, New York, NY 10036
- Number of Employees: No specific data available.
- Revenue: No specific data available.
- Known For: Digitalis Ventures is notable for investing in biotechnology companies across life sciences, health technologies, and services to improve both human and animal health. They are also recognized for writing and publishing on related health topics.
Products
Investment Areas
1. Life Sciences
- Investment in biotechnology companies leveraging breakthrough science to improve human health. This includes therapeutics, diagnostics, tools, and enabling technologies.
2. Health Technologies & Services
- Investment in technology-enabled solutions for improving access to care and health outcomes, while reducing costs.
3. Animal Health
- Through Companion Funds, investments are made in companies focused on improving animal health using breakthrough science, technology, and design.
Key Features
- Providing creative financing options and support to early-stage companies.
- Building public-private partnerships to tackle barriers in health solutions.
- Publishing insights and research through "Notes" on various topics within human and animal health sciences.
Recent Developments
- Portfolio News:
- Terray Therapeutics: Recently raised $120M and teamed up with Gilead for R&D, with plans to advance its generative AI pipeline.
- Switch Therapeutics: Developing RNAi therapies, announced a candidate for treating Alzheimer's.
- Elemental Machines: Launched new solutions for lab monitoring and expanded European operations.
- Partnerships:
- Protect Animal Health & Rejuvenate Bio: Partnered to tackle canine heart disease.
- Mars Petcare: Collaboration through Digitalis Companion Funds for improving animal health.
- Funding and Awards:
- Nuvig Therapeutics: Completed $161M Series B backed by Sanofi for autoimmune therapy.
- Alpha-9 Oncology: Secured $175 million in Series C financing.
- Expressable: Awarded accreditation from The Joint Commission for their speech therapy programs.
- Innovations and Launches:
- EpiBiologics: Presenting new data on protein degradation technology.
- Code Ocean: Recognized by 2023 BioTech Breakthrough Awards.
- Native Pet: Launched new science-backed pet supplements approved by PetSmart stores.
Additional Company Insights
- Digitalis Commons: The non-profit arm focusing on developing solutions that have a large-scale impact on health problems by building partnerships and advancing public interest technologies.
- The Name: Inspired by the Digitalis plant, known for its historical significance in heart disease treatments and the scientific legacy of Dr. Thomas W. Smith.
Note: The information above is compiled based on available data, and some fields may have unspecified details due to a lack of publicly available information.
